Frequency

Report 4 Downloads 220 Views
Invasive  Cervical  Cancer  Audit   V.  Mistry,  S.  Rajkumar,  G.  Lane,  G.  Majeed   Guy’s  and  St  Thomas’  NHS  Founda8on  Trust,  London,  UK   Graph  2  

Results  

The   NHS   Cervical   Screening   Programme   (NHSCSP)   in   England   provides   screening   to   approximately   14   million   women.   Due   to   its   success,   cervical   cancer   is   regarded   as   a   preventable   disease,   and   the   development   of   invasive  cancer  considered  an  adverse  event  requiring  inves8ga8on.       Since   April   2007,   the   NHSCSP   has   conducted   an   annual   na8onwide   audit   using  data  from  regional  Quality  Assurance  Reference  Centres  (QARCs).  This   acts   as   a   quality   control   tool   by   highligh8ng   deficiencies   in   the   screening   process   and   providing   informa8on   to   healthcare   professionals   in   order   to   guide   improvement.   Furthermore,   as   part   of   the   Duty   of   Candour,   it   is   a   requirement   that   all   cervical   cancer   pa8ents   are   offered   the   findings   of   a   review  into  their  screening  history.       Unfortunately,   this   na8onwide   audit   does   not   present   the   data   at   a   local   NHS  Trust  level;  as  such,  it  is  difficult  for  individual  units  to  obtain  applicable   learning  points.    

1)  20   pa8ents   were   diagnosed   with   invasive   cervical   carcinoma,   with   18   (90%)  being  of  the  squamous  subtype  (graph  1).     2)  9   pa8ents   (45%)   were   diagnosed   via   the   NHSCSP;   8   of   these   had   an   Interna8onal  Federa8on  of  Gynecology  and  Obstetrics  (FIGO)  stage  ≤1B.   The   remaining   11   pa8ents   were   diagnosed   following   presenta8on   with   symptoms;  only  2  had  a  FIGO  stage  ≤1B  (table  1  and  graph  2).       3)  NHSCSP   compliance   was:   20%   complete,   40%   incomplete   and   40%   never   had   a   smear   (graph   3).   FIGO   stage   ≥3B   at   diagnosis   was   only   seen   in   those   with   incomplete   or   no   screening   history.   Possible   reasons   for   screening  non-­‐compliance  can  be  seen  in  table  2.     4)  All  pa8ents  were  discussed  at  a  mul8disciplinary  mee8ng  (MDM)  and  all   recommended  treatments  were  appropriate  for  disease  stage.     5)  Mortality   rate   was   10%.   Characteris8cs   of   those   that   died   can   be   seen   in     table  3.     6)  Disclosure  lelers  were  offered  to  17  pa8ents  (85%).  3  accepted  a  review   of   their   NHSCSP   screening   history,   and   of   these,   2   had   cytological   undercall  at  some  point  during  their  screening.   Graph  1  

3B  

8  

3A   6  

2B  

4  

2A  

2  

1B1   1A1   Screen  detected  

Graph  3  

Pathway  

Opportunis8c  symptoms  

Screening  compliance  vs  FIGO  stage  at  diagnosis  

9  

4B  

8  

4A  

7  

20   18   16   14   12   10   8   6   4   2   0  

3B  

6  

3A  

5   4  

2B  

3  

2A  

2  

1B1  

1  

1A1  

0  

Methods   Table  1  

4A  

0  

Cervical  carcinoma  histology  

Squamous  

Retrospec8ve   study   of   all   pa8ents   diagnosed   with   invasive   cervical   carcinoma  at  Guy’s  and  St  Thomas’  NHS  Founda8on  Trust  (London,  England)   between  1st  January  to  31st  December  2014.       Informa8on  was  sought  from  pa8ents’  medical  notes,  the  Trust’s  Electronic   Pa8ent   Record   (EPR)   soWware   and   the   Na8onal   Health   Authority   Informa8on  System  (NHAIS)  via  the  ‘Open  Exeter’  database.       Data  were  collected  onto  bespoke  proformas  and  analysed  using  MicrosoW   Excel  for  Mac  2011  (Redmond,  USA).  

4B  

10  

Frequency  

To   conduct   an   equivalent   NHSCSP   audit   of   invasive   cervical   cancer   in   pa8ents   at   a   single   gynaecological-­‐oncology   Ter8ary   Referral   Centre   in   central  London.  The  specific  objec8ves  were  to  determine:       1)  Incidence  of  invasive  cervical  cancer     2)  Factors  contribu8ng  to  cervical  cancer  development     3)  Standards  of  management  once  diagnosis  is  established     4)  Cervical  cancer  mortality  rate     5)  If  cervical  cancer  pa8ents  were  offered  the  findings  of  a  review  into  their   screening  history  

Frequency  

Aims  

 

Pathway  of  diagnosis  vs  FIGO  stage  at  diagnosis

12  

Frequency  

Introduc>on  

Histological  type  

Symptoms  at  presenta>on  

Irregular  vaginal  bleeding  

Complete  

Adenocarcinoma  

Incomplete  

Never  

Compliance  

Frequency   4  

Table                    2                    Possible  reasons  for  non-­‐compliance    

                                   (not  mutually  exclusive)  

Frequency  

Non-­‐UK  na8onal  

4  

Civil  partnership  

2  

Psychiatric  comorbidity  

2  

Post-­‐menopausal  bleeding  

2  

Post-­‐coital  bleeding  

2  

Abdominal  pain  

2  

Drug  use  

1  

Intermenstrual  bleeding  

1  

Nursing  home  resident  

1  

Table                3                    Characteris>cs  of  pa>ents  that  died  

Results  

Age  

>65  years  

FIGO  stage  at  diagnosis  

4A  &  4B  

Pathway  of  diagnosis  

Symptoms  

Cervical  screening  history  

Never  

Management  

Pallia8ve  

           

Conclusions   Pa8ents  with  a  less  advanced  stage  of  cervical  cancer  at  diagnosis  tend  to  be   those   who   are   asymptoma8c,   screen-­‐detected   and   who   have   complete   compliance  with  the  NHSCSP;  this  highlights  that  the  NHS  Cervical  Screening   Programme   works.   Despite   this,   only   1   in   5   women   adhered   to   the   recommended   screening   intervals;   however   there   appear   to   be   characteris8cs  in  common  to  those  with  poor  compliance.       Pa8ents’  acceptance  of  a  review  of  their  screening  history  is  low;  although   upon  disclosure  of  the  review,  it  was  shown  that  cytological  undercall  does   occur.   Even   though   the   mortality   rate   appears   high,   we   are   unable   to   interpret  this  due  to  the  small  number  of  pa8ents  included  in  this  audit.  

Recommenda>ons   1)  Target   pa8ents   with   poor   compliance   and   those   with   characteris8cs   that   may  pre-­‐dispose  them  to  incomplete  screening     2)  Ensure   standards   within   cytology,   colposcopy   and   histology   to   reduce   undercall  and  subsequent  inappropriate  ac8on     3)  The   results   of   the   NHSCSP   screening   history   review   should   be   more   accessible  in  order  to  aid  data  collec8on  for  audits  at  a  local  level     4)  Re-­‐audit  in  1  year  (2015  cohort)      

Acknowledgements   The   authors   would   like   to   thank   the   following   members   of   the   mul8disciplinary   team,   without   whom   the   above   audit   would   not   have   occurred:     Mr   Ali   Kubba,   Mr   Rahul   Nath,   Mr   Gautam   Mehra,   Helen   Eageling   and   Marian  DeVries.  

20th  –  22nd  June  2016